Skip to main content Accessibility help
×
Hostname: page-component-7479d7b7d-rvbq7 Total loading time: 0 Render date: 2024-07-12T17:58:51.434Z Has data issue: false hasContentIssue false

146 - Verapamil

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Calan, Cordilox, Securon, Verapress, Vertab, Univer, Covera-HS, Verelan, Isoptin SR

Generic?

• Yes

Class

• Calcium channel blocker

Commonly Prescribed for

(FDA approved in bold)

Angina (vasospastic, unstable, or effort associated)

Essential hypertension

Paroxysmal supraventricular tachycardia, atrial fibrillation/flutter (IV formulation, immediate-release tablet)

• Prophylaxis of hemiplegic migraine or migraine with prolonged aura

• Cluster headache prophylaxis

• Peyronie's disease, plantar fibromatosis, Dupuytren's disease (gel)

How the Drug Works

• Cluster: proposed prior mechanisms included inhibition of smooth muscle contraction preventing arterial spasm and hypoxia, prevention of vasoconstriction or platelet aggregation, and alterations of serotonin release and uptake

• Voltage-gated calcium channels mediate calcium influx and are important in regulating neurotransmitter and hormone release

How Long Until It Works

• Migraines: may decrease in as little as 2 weeks, but can take up to 3 months on a stable dose to see full effect

• Cluster: usually effective in weeks

If It Works

• Migraine: goal is a 50% or greater reduction in migraine frequency or severity. Consider tapering or stopping if headaches remit for more than 6 months or if considering pregnancy

• Cluster: reduction in the severity or frequency of attacks

If It Doesn't Work

• Increase to highest tolerated dose

• Migraine/cluster: address other issues, such as medication overuse, other coexisting medical disorders, such as anxiety, and consider changing to another agent or adding a second agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• Cluster: at the start of the cycle can use a corticosteroid slam and taper. Lithium, topiramate are effective preventive medications for cluster patients

Tests

• At higher doses, monitor ECG for PR interval

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Direct effects of calcium receptor antagonism, slowing of AV conduction

Notable AEs

• Bradycardia, hypotension, weakness, headache

• Constipation, nausea, myalgia

• Allergic rhinitis, ankle edema, gingival hyperplasia

• First-degree AV block

• Upper respiratory infection, flu-like syndrome

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 539 - 542
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Verapamil
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.147
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Verapamil
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.147
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Verapamil
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.147
Available formats
×